Benign gastric ulcer and duodenal ulcer |
Treatment dose |
150 mg twice daily or 300 mg single dose at bed time for 4 to 8 weeks. A dose of 300 mg twice daily for 4 weeks can be given in duodenal ulcer to achieve a higher healing rate |
Maintenance dose |
150 mg daily at bed time |
NSAID-induced ulcer |
150 mg twice daily or 300 mg single dose at bed time for 8 weeks |
Prophylaxis of NSAID-induced ulcer |
150 mg-300 mg twice daily |
Duodenal ulcer associated with H. pylori |
300 mg Ranitidine once daily or 150 mg twice daily + 750 mg Amoxicillin 3 times a day + 500 mg Metronidazole 3 times a day for 2 weeks. Therapy with Ranitidine should then be continued for a further 2 weeks |
Chronic episodic dyspepsia |
150 mg twice daily or 300 mg single dose at bed time for 6 weeks |
Gastroesophageal reflux disease (GERD) |
Normal |
150 mg twice daily or 300 mg single dose at bed time for 8 weeks or if necessary 12 weeks |
Moderate to severe |
600 mg daily in 2-4 divided doses for up to 12 weeks |
Maintenance dose |
150 mg twice daily |
Pathological acid hypersecretory conditions, such as Zollinger-Ellison Syndrome (ZES) |
150 mg 3 times daily; dose up to 6 g daily in divided doses have been used |
Gastric acid reduction (prophylaxis of acid aspiration) |
In obstetrics |
150 mg at onset of labour, then every 6 hours |
Surgical procedures |
150 mg 2 hours before induction of anaesthesia and preferably also 150 mg the previous evening |
Prophylaxis of stress ulcer |
After IV Ranitidine administration, doses of 150 mg twice daily may be given when oral feeding commences |
In renal impairment the mean elimination half-life of Ranitidine is increased to double and therefore dosage of Ranitidine should be reduced in patients with severe renal impairment and suggested doses is 150 mg daily. Children : The recommended oral dose for the treatment of duodenal and gastric ulcer in children is 2 to 4 mg/kg twice daily to a maximum of 300 mg/day.